European equities traded in the US as American depositary receipts were tracking higher late Tuesday morning, rising 0.57% to 1,402.56 on the S&P Europe Select ADR Index. From continental Europe, the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation to Autolus ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late Friday announced it has granted a conditional ...

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted ...

Autolus Therapeutics, a UCL spinout company, has received authorisation from the UK Medicines and Healthcare products ...

Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Traders use this information to analyze potential trades and assess market sentiment for Autolus Therapeutics. In The Money Expiration Date April 17, 2025 May 16, 2025 June 20, 2025 September 19 ...

View the AUTL option chain and compare options of Autolus Therapeutics Ltd stock. Analyze the various options available, including call options (the right to buy) and put options (the right to ...

Utilizing immune cells called T cells that have been genetically modified in a lab to improve their ability to recognize and eliminate cancer cells, CAR T-cell therapy is a form of cancer ...

Tvardi Therapeutics, Inc. (Nasdaq: TVRD), a clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrosis-driven diseases, visits the Nasdaq MarketSite in Times Square.